[1] The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007

[2] Family physicians' knowledge and screening of chronic hepatitis and liver cancer

[3] The Institute of Medicine report on viral hepatitis: a call to action

[4] Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

[5] the efficacy of administration of a single booster dose of hepatitis b vaccine in 5-7 year old children in kogiloyeh and boyerahmad province- iran

[6] Chronic hepatitis B

[7] A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

[8] Gold nanoparticles and hepatitis B virus

[9] Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

[10] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[11] Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

[12] Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

[13] Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

[14] Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

[15] Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

[16] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[17] Safety and efficacy of entecavir for the treatment of chronic hepatitis B

[18] New approaches in the management of chronic hepatitis B: role of tenofovir

[19] Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

[20] Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

[21] In Silico Screening of Aptamers Configuration against Hepatitis B Surface Antigen

[22] Seroprevalence of Hepatitis B Virus and Associated Factors among Health Professionals in University of Gondar Hospital, Northwest Ethiopia

[23] Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

[24] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[25] Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

[26] Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

[27] Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

[28] Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

[29] Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

[30] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[31] Safety and efficacy of entecavir for the treatment of chronic hepatitis B

[32] New approaches in the management of chronic hepatitis B: role of tenofovir

[33] Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

[34] Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

[35] Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.

[36] Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.

[37] What is the optimal timing of antiviral treatment in pregnant hepatitis B carrier with extremely high viral load?

[38] High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

[39] Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study

[40] Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection.

[41] The impact of schistosomiasis co-infection in the presentation of viral hepatitis B in migrants: An observational study in non-endemic area.

[42] Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity.

[43] Electronic health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection

[44] Seroprevalence of hepatitis B and C viruses among medical waste handlers at Gondar town Health institutions, Northwest Ethiopia

[45] Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.

[46] Association of rs10204525 genotype GG and rs2227982 CC combination in programmed cell death 1 with hepatitis B virus infection risk.

[47] Targeting Hepatitis B Virus cccDNA and HBx: Recent Advances and New Approaches.

[48] Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.

[49] Assessing the knowledge of expectant mothers on mother–to-child transmission of viral hepatitis B in Upper West region of Ghana

[50] LncRNA H19/microRNA-675/PPARα axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt/mTOR signalling

[51] Effect of a media intervention on hepatitis B screening among Vietnamese Americans.

[52] Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure.

[53] Correlation of CpG methylation of Pdcd1 gene with PD-1 expression on CD8 T cells and medical laboratory indicators in chronic hepatitis B infection.

[54] Metabolomics analysis of the saliva in patients with chronic hepatitis B using nuclear magnetic resonance: a pilot study.

[55] Maternal reasons for non-receipt of valid Hepatitis B birth dose among mother-infant pairs attending routine immunization clinics, South-east, Nigeria.

[56] Surveillance and impact of occult hepatitis B virus, SEN virus, and Torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection.

[57] Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review

[58] Evaluation of the /S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus.

[59] Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon

[60] Comparing the Effects of Different Story Types and Speakers in Hepatitis B Storytelling Videos.

[61] Propolis alleviates concanavalin A-induced hepatitis by modulating cytokine secretion and inhibition of reactive oxygen species.

[62] Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus.

[63] The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients

[64] Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.

[65] Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan

[66] Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.

[67] Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection

[68] One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor

[69] Ethics of HIV and hepatitis B cure research

[70] HIV through the looking glass: insights derived from Hepatitis B.

[71] A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis

[72] Response: Providing strong evidence of nosocomial outbreak of hepatitis B virus infection

[73] Acute Q Fever Hepatitis in Patients with and without Underlying Hepatitis B or C Virus Infection

[74] New blood-borne virus infections among organ transplant recipients: An Australian data-linked cohort study examining donor transmissions and other HIV, hepatitis C and hepatitis B notifications, 2000-2015

[75] Application of Hepatitis B Virus Genotyping and Phylogenetic Analysis in Intrafamilial Transmission of Hepatitis B Virus

[76] Impact of HEC72702 chirality on the selective inhibition of hepatitis B virus capsid dimer: A dynamics-structure-energetics perspective

[77] Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status

[78] [Safety and immunogenicity analysis of recombinant （hansenula polymorpha) hepatitis B vaccine （CpG ODN adjuvant) among adults: the preliminary results of phase I clinical trial]

[79] Response of Egyptian infants with protein calorie malnutrition to hepatitis B vaccination

[80] Simultaneous Acute Hepatitis B Virus and Hepatitis C Virus Infection Leading to Fulminant Hepatitis and Subsequent Chronic Hepatitis C

[81] Response of Egyptian Infants with Protein Calorie Malnutrition to Hepatitis B Vaccination

[82] Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

[83] chronic active hepatitis b with hbv-associated nephropathy: close resemblance to lupus nephritis

[84] selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis b virus-infected patients

[85] relationship between hbv dna and hbeag in serum and hbcag and inflammation grade in liver tissue among patients with chronic hepatitis b

[86] screening and evaluation of chronic and occult hepatitis b in chemo – radiotherapy patients with cancer

[87] stimulation of cellular proliferation by hepatitis b virus x protein

[88] seropositivity of hepatitis b and c among syrian multitransfused patients with hemoglobinopathy

[89] survey of both hepatitis b virus (hbsag) and hepatitis c virus (hcv-ab) coinfection among hiv positive patients

[90] conhecimento dos obstetras sobre a transmissão vertical da hepatite b knowledge of obstetricians about the vertical transmission of hepatitis b virus

[91] risk factors and seroprevalence of hepatitis b, c, and d virus in hemodialysis patients in istanbul

[92] características da reação tipo 1 e associação com vírus b e c da hepatite na hanseníase type 1 reaction in leprosy: characteristics and association with hepatitis b and c viruses

[93] comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis b

[94] occult hepatitis b virus infection in liver transplant patients in a brazilian referral center

[95] real-time tissue elastography in the evaluation of liver cirrhosis in patients with chronic hepatitis b

[96] an investigation into the high prevalence of hepatitis b in a rural area of kerala state, india: hypothesis on chrysops sp. (diptera: tabanidae) transmission

[97] response to letter to the editor re ‘be cautious for exceptional results in evaluating the effect of adolescent booster of hepatitis b vaccine’

[98] intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis b patient with acute exacerbation

[99] values, preferences and current hepatitis b and c testing practices in low- and middle-income countries: results of a survey of end users and implementers

[100] common mutations of hepatitis b virus and their clinical significance

[101] primary hepatic small-cell carcinoma developed during antiviral treatment for chronic hepatitis b